[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharmacyte Biotech Inc (PMCB)

Pharmacyte Biotech Inc (PMCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,796
  • Shares Outstanding, K 10,736
  • Annual Sales, $ 0 K
  • Annual Income, $ 30,660 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.19
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.53
  • Most Recent Earnings $0.13 on 03/17/26
  • Next Earnings Date 08/14/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 633.20% (-272.75%)
  • Historical Volatility 63.04%
  • IV Percentile 88%
  • IV Rank 63.56%
  • IV High 959.87% on 11/06/25
  • IV Low 63.40% on 01/06/26
  • Expected Move (DTE 32) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 39
  • Open Int (30-Day) 1,346
  • Expected Range 0.6233 to 0.6233

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6100 +2.18%
on 07/20/26
0.8000 -22.09%
on 06/23/26
-0.0945 (-13.17%)
since 06/18/26
3-Month
0.6100 +2.18%
on 07/20/26
0.9700 -35.74%
on 05/14/26
-0.1407 (-18.42%)
since 04/20/26
52-Week
0.6100 +2.18%
on 07/20/26
1.5100 -58.72%
on 12/05/25
-0.4067 (-39.49%)
since 07/18/25

Most Recent Stories

More News
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company’s...

PMCB : 0.6233 (-1.53%)
FEMY : 3.27 (+8.64%)
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner’s 2025 Hype Cycle for Data Center Infrastructure...

PMCB : 0.6233 (-1.53%)
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, PharmaCyte had...

PMCB : 0.6233 (-1.53%)
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financing with existing investors...

PMCB : 0.6233 (-1.53%)
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box ® for potential...

PMCB : 0.6233 (-1.53%)
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology,...

PMCB : 0.6233 (-1.53%)
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology,...

PMCB : 0.6233 (-1.53%)

Business Summary

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company. It is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). The Company's patented technology is...

See More

Key Turning Points

3rd Resistance Point 0.6940
2nd Resistance Point 0.6746
1st Resistance Point 0.6489
Last Price 0.6233
1st Support Level 0.6038
2nd Support Level 0.5844
3rd Support Level 0.5587

See More

52-Week High 1.5100
Fibonacci 61.8% 1.1662
Fibonacci 50% 1.0600
Fibonacci 38.2% 0.9538
Last Price 0.6233
52-Week Low 0.6100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.